Your browser is no longer supported. Please, upgrade your browser.
Settings
ARIA Ariad Pharmaceuticals Inc. daily Stock Chart
ARIA [NASD]
Ariad Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.23 Insider Own1.40% Shs Outstand188.40M Perf Week17.26%
Market Cap1.79B Forward P/E- EPS next Y-0.44 Insider Trans-14.94% Shs Float184.93M Perf Month27.48%
Income-232.30M PEG- EPS next Q-0.11 Inst Own74.10% Short Float17.80% Perf Quarter32.45%
Sales130.40M P/S13.74 EPS this Y-40.80% Inst Trans1.32% Short Ratio6.92 Perf Half Y89.44%
Book/sh-0.81 P/B- EPS next Y39.70% ROA-42.80% Target Price9.38 Perf Year21.15%
Cash/sh0.89 P/C10.65 EPS next 5Y30.00% ROE289.80% 52W Range4.37 - 10.07 Perf YTD52.16%
Dividend- P/FCF- EPS past 5Y-29.50% ROI-62.90% 52W High-5.56% Beta1.91
Dividend %- Quick Ratio1.70 Sales past 5Y-7.90% Gross Margin98.50% 52W Low117.62% ATR0.40
Employees459 Current Ratio1.70 Sales Q/Q48.30% Oper. Margin- RSI (14)75.80 Volatility5.28% 4.41%
OptionableYes Debt/Eq- EPS Q/Q-0.80% Profit Margin- Rel Volume3.33 Prev Close9.47
ShortableYes LT Debt/Eq- EarningsJul 28 BMO Payout- Avg Volume4.75M Price9.51
Recom2.40 SMA2024.57% SMA5020.95% SMA20042.50% Volume15,838,797 Change0.42%
May-11-16Reiterated Barclays Underweight $6 → $8
Jan-19-16Initiated Barclays Underweight $6
May-08-15Reiterated UBS Neutral $7 → $9
Mar-25-14Resumed HC Wainwright Buy $14
Feb-26-14Upgrade Maxim Group Hold → Buy $11
Feb-26-14Downgrade Chardan Capital Markets Buy → Neutral
Jan-24-14Upgrade BMO Capital Markets Market Perform → Outperform $8 → $14
Jan-06-14Reiterated UBS Neutral $2.50 → $7.50
Dec-23-13Upgrade Chardan Capital Markets Neutral → Buy $9
Dec-20-13Reiterated BMO Capital Markets Market Perform $4 → $8
Dec-10-13Upgrade Stifel Hold → Buy $7
Oct-21-13Downgrade RBC Capital Mkts Outperform → Sector Perform $9 → $4
Oct-14-13Downgrade Argus Hold → Sell
Oct-10-13Reiterated Oppenheimer Outperform $24 → $7
Oct-10-13Downgrade Summer Street Research Buy → Neutral
Oct-10-13Downgrade Chardan Capital Markets Buy → Neutral
Oct-10-13Downgrade Barclays Overweight → Underweight $25 → $4
Oct-09-13Downgrade Maxim Group Buy → Hold $24
Sep-30-13Upgrade Oppenheimer Perform → Outperform $23 → $24
Sep-30-13Reiterated Maxim Group Buy $26 → $24
Jul-29-16 09:23AM  ARIAD's (ARIA) Stock Up on Q2 Earnings & Revenue Beat
Jul-28-16 01:37PM  Todays Trending Stocks: Pioneer, Ariad, Hershey, and 2 More at Insider Monkey +12.47%
12:18PM  ARIAD (ARIA) Stock Pops After Q2 Beat
09:12AM  ARIAD (ARIA) Swings to Earnings in Q2, Revenues Beat
08:56AM  Ariad beats 2Q profit forecasts
08:30AM  ARIAD Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today
07:36AM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure
07:35AM  ARIAD Reports Second Quarter and First Half 2016 Financial Results Business Wire
07:07AM  Q2 2016 ARIAD Pharmaceuticals Inc Earnings Release - Before Market Open
Jul-27-16 09:47AM  Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More
Jul-26-16 06:58AM  ARIAD (ARIA) to Report Q2 Earnings: Will the Stock Surprise?
Jul-23-16 03:23PM  Cancer Stocks: 2 to Buy, 1 to Avoid at Motley Fool
Jul-22-16 04:07PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Financial Statemen
08:03AM  ARIAD Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARIA-US : July 22, 2016
Jul-21-16 11:27AM  These 5 Stocks Under $10 Are Set to Soar Higher
08:00AM  Ariad Pharmaceuticals (ARIA) In Focus: Stock Jumps 8.2%
Jul-19-16 02:31PM  Is Agenus or Ariad Pharmaceuticals the Better Long-Term Buy? at Motley Fool
Jul-05-16 07:35AM  ARIAD to Webcast Conference Call on Second Quarter 2016 Financial Results Business Wire
Jun-28-16 09:31AM  4 Biotechs with Blockbuster Potential for Multiple Cancer Indications +5.49%
Jun-24-16 07:35AM  ARIAD Announces Webcast of Its Annual Stockholders Meeting Business Wire
Jun-23-16 06:55AM  Five companies that could buy Ariad this year for as much as $2.9B at bizjournals.com
Jun-21-16 11:21AM  ARIAD Pharmaceuticals, Inc. Value Analysis (NASDAQ:ARIA) : June 21, 2016
Jun-20-16 08:33AM  ARIAD Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARIA-US : June 20, 2016
Jun-17-16 05:30PM  Why Ariad Pharmaceuticals, Nevsun Resources, and Ctrip.com International Slumped Today at Motley Fool -6.47%
12:33PM  ARIAD Completes Strategic Review and Announces Plans for Growth Business Wire
10:56AM  Why Mosaic, Vale, and Three Other Stocks Are in the Spotlight at Insider Monkey
10:36AM  ARIAD Initiates Submission Of NDA For Brigatinib Ahead Of Plan
07:45AM  ARIAD Announces Distribution Agreements for Iclusig® in Latin America and the Middle East/North Africa Business Wire
07:35AM  ARIAD Initiates Submission of New Drug Application for Brigatinib to the U.S. Food and Drug Administration Ahead of Plan Business Wire
Jun-14-16 06:25PM  ARIAD (ARIA) Presents Long-Term Phase II Data on Iclusig
Jun-13-16 10:46AM  Ariad Reveals Ponatinib's Long-Term Safety And Efficacy Data From Stage 2 Clinical Study
07:35AM  ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial Business Wire
Jun-09-16 04:42PM  3 Reasons Ariad Pharmaceuticals Inc. Stock Rose 23.3% in May at Motley Fool
Jun-08-16 05:25PM  Ariad Pharmaceuticals, Inc. (ARIA) To Seek Regulatory Clearance For Brigatinib In 3Q at Insider Monkey
02:21PM  What Helped Incyte Report Growth in 1Q16?
09:02AM  Research Coverage Scans Stocks on the Biotechnology Industry for Today
07:35AM  ARIAD to Host Analyst & Investor Day in New York City Business Wire
Jun-07-16 04:09PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
12:00PM  ARIAD (ARIA) Presents Phase II Study Data on Cancer Drug
Jun-06-16 02:13PM  Ariad confident on cancer drug data
01:57PM  Why Tyson Foods, Fitbit, and Three Other Stocks Are Down As Major Indices Are in Green at Insider Monkey
10:36AM  Winners And Losers From Cancer's Big Event at Forbes
08:00AM  ARIAD Pharmaceuticals Investor and Analyst Briefing and Webcast Call scheduled for 8:00 am ET today
07:35AM  ARIAD's Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate and 12.9-Month Median Progression-Free Survival in ALTA Study Business Wire
Jun-04-16 07:35AM  ARIAD Presents Long-Term Phase 1/2 Trial Follow up on Investigational Drug Brigatinib with Median Time on Treatment of 17 Months in ALK+ NSCLC Patients Business Wire
07:35AM  ARIAD Presents Data from Mutational Profiling in Crizotinib-Resistant Patients Treated with Investigational Medicine Brigatinib Showing Similar Response Rates in Patients with and without Secondary ALK Mutations Business Wire
Jun-03-16 06:05PM  4 Catalysts Send Incyte Corporation 17% Higher in May at Motley Fool
01:20PM  The buzz from ASCO
12:25PM  On tap at ASCO
Jun-02-16 11:04AM  Biotech Stocks: Are They Back? at Investopedia
08:31AM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta
07:35AM  ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig® Business Wire
Jun-01-16 05:05PM  ARIAD (ARIA) Commences Phase I/II Study on Cancer Drug
08:25AM  Ariad Pharmaceuticals (ARIA) Jumps: Stock Moves Up 7.8%
07:35AM  ARIAD to Present at the Jefferies 2016 Global Healthcare Conference Business Wire
May-31-16 11:25AM  Ariad Pharmaceuticals Is Nearly Done Building Base Pattern +7.80%
08:57AM  Surging Earnings Estimates Signal Good News for Ariad Pharmaceuticals (ARIA)
07:35AM  ARIAD Announces Initiation of Phase 1/2 Clinical Trial of AP32788, an Investigational Oral Inhibitor of EGFR and HER2, in Patients with Non-Small Cell Lung Cancer Business Wire
May-26-16 04:09PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
May-24-16 09:25AM  ARIAD Announces Appointment of Jennifer L. Herron as Chief Commercial Officer Business Wire
May-20-16 09:28AM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of In
May-19-16 06:58PM  ETFs with exposure to ARIAD Pharmaceuticals, Inc. : May 19, 2016
04:12PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
01:04PM  ARIAD PHARMACEUTICALS INC Financials
07:35AM  ARIAD Announces Pricing and Reimbursement for Iclusig in France Business Wire
May-18-16 05:23PM  Biotech stocks on the move
05:08PM  ARIAD Announces Data Presentations at the 2016 ASCO Annual Meeting Business Wire
May-16-16 01:02PM  Noteworthy Insider Trading Activity at These 5 Companies as Insider Buying Ratio Increases at Insider Monkey
May-13-16 09:30AM  The Zacks Analyst Blog Highlights: Medivation, Juno, Kite, ARIAD and AbbVie
May-12-16 12:07PM  Biotech Stock Roundup: Medivation Buyout Rumors Continue, NewLink Plunges on Late-Stage Data
10:39AM  ARIAD Pharmaceuticals, Inc. :ARIA-US: Earnings Analysis: Q1, 2016 By the Numbers
07:40AM  ASCO Could Make or Break These 7 Cancer Drug Trials at 24/7 Wall St.
May-11-16 07:47AM  ARIAD (ARIA) Q1 Loss Narrower But Revenues Disappoint (Revised)
May-10-16 11:13AM  Edited Transcript of ARIA earnings conference call or presentation 10-May-16 12:30pm GMT +6.41%
09:18AM  ARIAD's (ARIA) Q1 Loss Narrower than Expected
08:30AM  ARIAD Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today
07:49AM  Ariad reports 1Q loss AP
07:46AM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure EDGAR Online
07:35AM  ARIAD Reports First Quarter 2016 Financial Results and Progress on Strategic Review Business Wire
07:07AM  Q1 2016 ARIAD Pharmaceuticals Inc Earnings Release - Before Market Open CCBN
May-09-16 01:02PM  Is It Time to Buy Ariad Pharmaceuticals' Stock? at Motley Fool
12:27PM  $275M deal: Incyte to acquire biopharm firm's European operations at American City Business Journals
11:29AM  Ariad sells European operations for $140M upfront plus royalties at American City Business Journals
10:57AM  Incyte Buys European Business Hub From Ariad Pharma at TheStreet
10:13AM  Drug Stocks Reporting on May 10: XON, ARIA, CPRX & More Zacks
07:17AM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financ EDGAR Online
07:00AM  Incyte and ARIAD Announce Agreement for Incyte to Acquire ARIADs European Operations and In-license Iclusig® (ponatinib) in Europe Business Wire
May-08-16 09:45AM  4 Major FDA Decisions Expected by June at 24/7 Wall St.
May-06-16 04:11PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
11:51AM  Ariad appears on the upswing as investors renew hopes of a buyout at American City Business Journals
08:14AM  ARIAD (ARIA) to Report Q1 Earnings: Will the Stock Surprise? Zacks
Apr-26-16 07:35AM  ARIAD to Webcast Conference Call on First Quarter 2016 Financial Results Business Wire
Apr-25-16 04:07PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events EDGAR Online
Apr-19-16 07:35AM  ARIAD Announces Results of Preclinical Studies on AP32788 at the Annual Meeting of the American Association for Cancer Research Business Wire
Apr-18-16 02:16PM  ARIAD Gains on Updated Brigatinib Phase I/II Study Data
09:02AM  [$$] Clinical Development News, April 11-15 at The Wall Street Journal
Apr-15-16 07:35AM  ARIAD Presents Updated Phase 1/2 Clinical Data on Brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer Business Wire
Apr-12-16 11:38AM  Why one trader is selling Ariad calls
Apr-11-16 07:35AM  ARIAD Announces Initiation of Randomized, First-Line Phase 3 Trial of Brigatinib in Treatment of ALK-Positive Non-Small Cell Lung Cancer Business Wire
Mar-30-16 09:26AM  Ariad Pharmaceuticals Takes An Axe To Its Expenses at Motley Fool
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CLACKSON TIMOTHY PPresident, R&D, CSOJul 22Sale8.1118,286148,230248,208Jul 25 04:39 PM
Panayiotopoulos ParisPresident and CEOJul 13Option Exercise0.0066,6000154,689Jul 14 04:23 PM
CLACKSON TIMOTHY PPresident, R&D, CSOJul 01Option Exercise3.8861,422238,585297,916Jul 05 04:07 PM
CLACKSON TIMOTHY PPresident, R&D, CSOJul 01Sale7.4861,422459,634266,494Jul 05 04:07 PM
Cole Hugh MSVP, Chief Business OfficerJun 28Sale7.056,01242,38529,916Jun 29 04:25 PM
Cole Hugh MSVP, Chief Business OfficerJun 27Option Exercise0.0019,166035,928Jun 29 04:25 PM
CLACKSON TIMOTHY PPresident, R&D, CSOJun 22Sale7.2823,999174,638264,742Jun 23 04:11 PM
LAVIDAS ATHANESEDirectorJun 15Option Exercise6.5546,250302,788177,881Jun 15 04:19 PM
LAVIDAS ATHANESEDirectorJun 15Sale8.2446,250381,137131,631Jun 15 04:19 PM
Radaelli MassimoDirectorJun 14Option Exercise4.916,25030,688111,750Jun 14 06:13 PM
LAVIDAS ATHANESEDirectorJun 14Option Exercise6.4420,000128,800151,631Jun 15 04:19 PM
LAVIDAS ATHANESEDirectorJun 14Sale8.1420,000162,852131,631Jun 15 04:19 PM
Radaelli MassimoDirectorJun 14Sale8.136,25050,834105,500Jun 14 06:13 PM
Radaelli MassimoDirectorJun 13Option Exercise6.5779,731523,551185,231Jun 14 06:13 PM
LAVIDAS ATHANESEDirectorJun 13Option Exercise5.4910,00054,900141,631Jun 15 04:19 PM
LAVIDAS ATHANESEDirectorJun 13Sale8.2110,00082,050131,631Jun 15 04:19 PM
Radaelli MassimoDirectorJun 13Sale8.2579,731657,821105,500Jun 14 06:13 PM
Radaelli MassimoDirectorJun 10Option Exercise1.3522,58830,494128,088Jun 14 06:13 PM
Radaelli MassimoDirectorJun 10Sale8.3022,588187,480105,500Jun 14 06:13 PM
Panayiotopoulos ParisPresident and CEOMay 12Buy7.4126,990199,99688,089May 13 05:59 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMay 02Sale7.1311,70083,478306,503May 02 05:28 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityApr 29Option Exercise0.0017,3340172,422May 02 05:30 PM
Cantor Maria ESVP, Corporate AffairsApr 29Option Exercise0.0013,3340149,001May 02 05:32 PM
Haluska FrankSVP, Clinical R&D, CMOApr 29Option Exercise0.0017,3340164,345May 02 05:33 PM
Cole Hugh MSVP, Chief Business OfficerApr 29Option Exercise0.0017,334022,396May 02 05:29 PM
CLACKSON TIMOTHY PPresident, R&D, CSOApr 29Option Exercise0.0023,4000318,203May 02 05:28 PM
Duvall Martin JEVP, CCOApr 29Option Exercise0.0018,0000111,039May 02 05:26 PM
CLACKSON TIMOTHY PPresident, R&D, CSOApr 22Sale7.3721,409157,864294,803Apr 25 04:04 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 21Sale6.474,00025,871155,088Mar 22 04:02 PM
FITZGERALD EDWARD MExecutive VPMar 21Sale6.475,41735,037320,367Mar 22 04:01 PM
Haluska FrankSVP, Clinical R&D, CMOMar 21Sale6.473,57523,116147,011Mar 22 04:01 PM
BERSTEIN DAVID LSVP, Chief IP CounselMar 21Sale6.472,37515,356262,115Mar 22 04:02 PM
BERSTEIN DAVID LSVP, Chief IP CounselMar 19Option Exercise0.004,7500264,490Mar 22 04:02 PM
Haluska FrankSVP, Clinical R&D, CMOMar 19Option Exercise0.006,5000150,586Mar 22 04:01 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 19Option Exercise0.0010,8330345,463Mar 22 04:01 PM
FITZGERALD EDWARD MExecutive VPMar 19Option Exercise0.0010,8330325,784Mar 22 04:01 PM
Duvall Martin JEVP, CCOMar 19Option Exercise0.008,000097,039Mar 22 04:03 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 19Option Exercise0.008,0000159,088Mar 22 04:02 PM
Duvall Martin JEVP, CCOMar 19Sale6.474,00025,86793,039Mar 22 04:03 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 19Sale6.475,41735,039340,046Mar 22 04:01 PM
Cole Hugh MSVP, Chief Business OfficerMar 16Option Exercise6.217,50046,5757,500Mar 18 04:04 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 15Option Exercise1.303,7504,875154,838Mar 17 04:45 PM
BERSTEIN DAVID LSVP, Chief IP CounselMar 03Sale6.129,62558,887259,740Mar 03 08:08 PM
Duvall Martin JEVP, CCOMar 03Sale6.129,62558,86389,039Mar 03 08:07 PM
FITZGERALD EDWARD MExecutive VP, CFOMar 03Sale6.129,62558,866314,951Mar 03 08:12 PM
Haluska FrankSVP, Clinical R&D, CMOMar 03Sale6.1110,58864,733144,086Mar 03 07:58 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 03Sale6.119,62558,852151,088Mar 03 07:59 PM
Cantor Maria ESVP, Corporate AffairsMar 03Sale6.129,62558,869132,742Mar 03 08:00 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 03Sale6.129,62558,867334,630Mar 03 08:00 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 02Sale6.0025,047150,282344,255Mar 03 08:00 PM
FITZGERALD EDWARD MExecutive VP, CFOMar 01Option Exercise0.0019,2500324,576Mar 03 08:12 PM
Duvall Martin JEVP, CCOMar 01Option Exercise0.0019,250098,664Mar 03 08:07 PM
BERSTEIN DAVID LSVP, Chief IP CounselMar 01Option Exercise0.0019,2500269,365Mar 03 08:08 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 01Option Exercise0.0019,2500369,302Mar 03 08:00 PM
Cantor Maria ESVP, Corporate AffairsMar 01Option Exercise0.0019,2500142,367Mar 03 08:00 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 01Option Exercise0.0019,2500160,713Mar 03 07:59 PM
Haluska FrankSVP, Clinical R&D, CMOMar 01Option Exercise0.0019,2500154,674Mar 03 07:58 PM
DesRosier ThomasEVP, General CounselFeb 18Option Exercise0.0055,000055,000Mar 30 05:04 PM
Cantor Maria ESVP, Corporate AffairsFeb 01Option Exercise0.0029,3330139,250Feb 03 04:35 PM
FITZGERALD EDWARD MExecutive VP, CFOFeb 01Option Exercise0.0029,3330319,993Feb 03 04:37 PM
Haluska FrankSVP, Clinical R&D, CMOFeb 01Option Exercise0.0029,3330151,557Feb 03 04:39 PM
BERSTEIN DAVID LSVP, Chief IP CounselFeb 01Option Exercise0.0029,3330264,782Feb 03 04:38 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityFeb 01Option Exercise0.0029,3330156,130Feb 03 04:41 PM
CLACKSON TIMOTHY PPresident, R&D, CSOFeb 01Option Exercise0.0029,3330364,719Feb 03 04:43 PM
Duvall Martin JEVP, CCOFeb 01Option Exercise0.0029,333094,081Feb 03 04:46 PM
Panayiotopoulos ParisPresident and CEOFeb 01Buy4.9161,099299,99661,099Feb 03 05:43 PM
Duvall Martin JEVP, CCOFeb 01Sale4.8114,66770,57879,414Feb 03 04:46 PM
CLACKSON TIMOTHY PPresident, R&D, CSOFeb 01Sale4.8114,66770,517350,052Feb 03 04:43 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityFeb 01Sale4.8114,66770,548141,463Feb 03 04:41 PM
BERSTEIN DAVID LSVP, Chief IP CounselFeb 01Sale4.8114,66770,515250,115Feb 03 04:38 PM
Haluska FrankSVP, Clinical R&D, CMOFeb 01Sale4.8116,13377,587135,424Feb 03 04:39 PM
FITZGERALD EDWARD MExecutive VP, CFOFeb 01Sale4.8114,66770,515305,326Feb 03 04:37 PM
Cantor Maria ESVP, Corporate AffairsFeb 01Sale4.8216,13377,745123,117Feb 03 04:35 PM
BERGER HARVEY J M DChairman & CEODec 31Option Exercise0.00602,50001,814,239Jan 05 05:41 PM
BERSTEIN DAVID LSVP, Chief IP CounselSep 28Sale6.465,00032,316240,449Sep 28 05:02 PM
CLACKSON TIMOTHY PPresident, R&D, CSOSep 28Sale6.468,75056,560334,086Sep 28 05:36 PM
Haluska FrankSVP, Clinical R&D, CMOSep 28Sale6.465,50035,503122,224Sep 28 05:40 PM
FITZGERALD EDWARD MExecutive VP, CFOSep 28Sale6.468,75056,551289,231Sep 28 05:50 PM
Cantor Maria ESVP, Corporate AffairsSep 28Sale6.475,00032,327109,917Sep 28 05:57 PM
Duvall Martin JEVP, CCOSep 28Sale6.465,00032,31764,748Sep 28 06:09 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualitySep 28Sale6.465,00032,316126,797Sep 28 06:14 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualitySep 24Option Exercise0.0010,0000131,797Sep 28 06:14 PM
Duvall Martin JEVP, CCOSep 24Option Exercise0.0010,000069,748Sep 28 06:09 PM
Cantor Maria ESVP, Corporate AffairsSep 24Option Exercise0.0010,0000114,917Sep 28 05:57 PM
FITZGERALD EDWARD MExecutive VP, CFOSep 24Option Exercise0.0017,5000297,981Sep 28 05:50 PM
Haluska FrankSVP, Clinical R&D, CMOSep 24Option Exercise0.0010,0000127,724Sep 28 05:40 PM
CLACKSON TIMOTHY PPresident, R&D, CSOSep 24Option Exercise0.0017,5000342,836Sep 28 05:36 PM
BERSTEIN DAVID LSVP, Chief IP CounselSep 24Option Exercise0.0010,0000250,449Sep 28 05:02 PM
Cantor Maria ESVP, Corporate AffairsSep 01Sale9.112,69624,557104,917Sep 03 04:20 PM
Cantor Maria ESVP, Corporate AffairsAug 28Sale10.001,26812,680107,613Sep 01 05:14 PM
FITZGERALD EDWARD MExecutive VP, CFOAug 28Sale10.0032,858328,580280,481Sep 01 05:14 PM